The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)
dc.contributor.author | van Diessen, DJ | |
dc.contributor.author | De Ruysscher, D | |
dc.contributor.author | Sonke, JJ | |
dc.contributor.author | Damen, E | |
dc.contributor.author | Sikorska, K | |
dc.contributor.author | Reymen, B | |
dc.contributor.author | van Elmpt, W | |
dc.contributor.author | Westman, G | |
dc.contributor.author | Fredberg, PG | |
dc.contributor.author | Dieleman, E | |
dc.contributor.author | Bjorkestrand, H | |
dc.contributor.author | Faivre-Finn, Corinne | |
dc.contributor.author | Belderbos, J | |
dc.date.accessioned | 2018-12-05T10:35:49Z | |
dc.date.available | 2018-12-05T10:35:49Z | |
dc.date.issued | 2018 | en |
dc.identifier.citation | van Diessen J, De Ruysscher D, Sonke J-J, Damen E, Sikorska K, Reymen B, et al. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiotherapy and Oncology. 2018 Oct. | en |
dc.identifier.pmid | 30327236 | en |
dc.identifier.doi | 10.1016/j.radonc.2018.09.019 | en |
dc.identifier.uri | http://hdl.handle.net/10541/621355 | |
dc.description.abstract | BACKGROUND AND PURPOSE: The PET-boost randomized phase II trial (NCT01024829) investigated dose-escalation to the entire primary tumour or redistributed to regions of high pre-treatment FDG-uptake in inoperable non-small cell lung cancer (NSCLC) patients. We present a toxicity analysis of the 107 patients randomized in the study. MATERIALS AND METHODS: Patients with stage II-III NSCLC were treated with an isotoxic integrated boost of ?72?Gy in 24 fractions, with/without chemotherapy and strict dose limits. Toxicity was scored until death according to the CTCAEv3.0. RESULTS: 77 (72%) patients were treated with concurrent chemoradiotherapy. Acute and late ?G3 occurred in 41% and 25%. For concurrent (C) and sequential or radiotherapy alone (S), the most common acute ?G3 toxicities were: dysphagia in 14.3% (C) and 3.3% (S), dyspnoea in 2.6% (C) and 6.7% (S), pneumonitis in 0% (C) and 6.7% (S), cardiac toxicity in 6.5% (C) and 3.3% (S). Seventeen patients died of which in 13 patients a possible relation to treatment could not be excluded. In 10 of these 13 patients progressive disease was scored. Fatal pulmonary haemorrhages and oesophageal fistulae were observed in 9 patients. CONCLUSION: Personalized dose-escalation in inoperable NSCLC patients results in higher acute and late toxicity compared to conventional chemoradiotherapy. The toxicity, however, was within the boundaries of the pre-defined stopping rules. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.radonc.2018.09.019 | en |
dc.title | The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial) | en |
dc.type | Article | en |
dc.contributor.department | Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands | en |
dc.identifier.journal | Radiother Oncol | en |
dc.description.note | en] |